# ART 34 AMDT

Fuzzy technique; and

a rule-based classification step of arranging and normalizing the results obtained at the data mapping step, and thus generating a final rule base.

21. (amended) A biomarker or biomarkers for diagnosis of breast cancers, comprising a proteome pattern, wherein said proteome pattern is one or more selected from spots listed in Table 1.

22. (deleted)

COLITORIE

ATENT COOPERATION TREATY

Rec'd PCT/PTO

<del>-08 nc i</del>

1 0 AUG 2004

WIPO PCT

## **PCT**

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Artcle 36 and Rule 70)

Applicant's or agent's file reference OP020135	FOR FURTHER ACTION  SeeNotificationofTransmittalofInternationalPreliminary Examination Report (Form PCT/IPEA/416)							
International application No. PCT/KR2002/002427	International filing date(a 24 DECEMBER 20		Priority date (day/month/ye 08 APRIL 2002 (08.04.20					
International Patent Classification (IPC) or national classification and IPC								
IPC7 G01N 33/574								
Applicant								
BIOINFRA INC. et al								
<ol> <li>This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</li> <li>This REPORT consists of a total of4sheets, including this cover sheet.</li> <li>This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</li> </ol>								
These annexes consist of a total of sheets.								
This report contains indications relating to the following items:  I X Basis of the report  II Priority  III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability  IV Lack of unity of invention  V X Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement  VI Certain documents cited  VII Certain defects in the international application  VIII Certain observations on the international application								
Date of submission of the demand		Date of completion of	this report					
06 NOVEMBER 2003 (06.11.2003)		29 JULY 200	4 (29.07.2004)					
Name and mailing address of the IPEA/KR		Authorized officer	· · · · · · · · · · · · · · · · · · ·	SO INTILLIA				
Korean Intellectual Property 920 Dunsan-dong, Seo-gu, Republic of Korea	Daejeon 302-701,	SHIN, Weon H	ye	(PF1011)				
Facsimile No. 82-42-472-7140		Telephone No. 82-42	2-481-8155	WIM				

I.	I. Basis of the report					
. With regard to the elements of the international application:*						
	the international application as originally filed					
	$\overline{\mathbb{X}}$	the description:	, as originally filed			
	_	pages 1-24	, filed with the demand			
		pages, filed with the letter of				
	X	the claims:				
	ല	pages 25-29	, as originally filed			
		pages 23-29 pages , as amended (together pages	, mod with the deministra			
		pages 30 , filed with the letter of	18/06/2004			
	П	the drawings:				
		2000	, as originally filed			
		pages filed with the letter of	, filed with the definance			
		the sequence listing part of the description:				
-		pages	, as originally filed, filed with the demand			
		pages, filed with the letter of	, med with the demand			
2.	the	th regard to the language, all the elements marked above were available or furnished to the international application was filed, unless otherwise indicated under this item. esse elements were available or furnished to this Authority in the following language the language of a translation furnished for the purposes of international search (under the language of publication of the international application (under Rule 48.3(b)). the language of the translation furnished for the purposes of international prelimination 55.3).	English which is Rule 23.1(b)).			
3	3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:					
		contained inthe international application in written form.	•			
		filed together with the international application in computer readable form.				
		furnished subsequently to this Authority in written form.				
		furnished subsequently to this Authority in computer readable form	at a leave of the disclosure in the			
	The statement that the subsequently furnished written sequence listing does not go beyond the disc losure in international applicationas as filed has been furinshed.					
		The statement that the information recorded in computer readable form is identic been furnished.	al to the written sequence using has			
4.	X	The amendments have resulted in the cancellation of:				
		the description, pages				
		X the claims, Nos. 22				
		the drawings, sheet				
5.		This report has been established as if (some of) the amendments had not been me go beyond the disclosure as filed, as indicated in the Supplemental Box(Rule 70.2)	ade, since they have been considered to (c)).**			
•	in i	placement sheets which have been furnished to the receiving Office in response to an im this opinion as "originally filed." and are not annexed to this report since they do no d 70.17).	nitation under Article 14 are referred to t contain amendments (Rules 70.16			
	* An	ny replacement sheet containing such amendments must be referred to under item I and	annexed to this report.			

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicabili	i <b>ty;</b>
citations and explanations supporting such statement	

1.	Statement Novelty (N)	Claims	1-21	YES
	2.6, (2.)	Claims		МО
	Inventive step (IS)	Claims Claims	1-21	YES NO
	Industrial applicability (IA)	Claims Claims	1-21	yes no

2. Citations and explanations (Rule 70.7)

Reference is made to the following document from the International Search Report (ISR). D1: KR 2000-0052802 (patent family member: EP 934409)


1. Novelty & Inventive step

Objects of the present invention are to provide a system (claims 1~11) and a method (claims 12~20) for detection of cancer, by generating a serum proteome standard by an image mining technique, and to provide biomarkers specific to breast cancer (claim 21). The present invention (claims 1 & 12) comprises input means/step for inputting serum proteome; proteome standard production means/step; proteome comparison means/step; disease analysis means/step; and output means/step.

D1 is considered to represent the most relevant state of the art for the subject matter of present invention with respect to identifying and characterizing changes in proteomes by a computer-based system, which aligns a new proteome image with the master composite image that is corresponding to the proteome standard of the present invention. It relates to methods and computer systems for analyzing cell proteomes to characterize proteins that are up- or down-regulated under different conditions, such as under abnormal(diseased) or compound-treated conditions.

- Continued in Supplemental Box

### INTERNATIONAL PREDMINARY EXAMINATION REPORT



Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

#### Continuation of:

Box V

However, the subject matters of claims 1 & 12 of the present invention are different from what D1 discloses in that an image mining technique is introduced to the proteome analyses of the present invention, wherein the proteome standard is generated by an image mining tool, which employs a genetic algorithm, a support vector machine, and a fuzzy rule-based classification means is also used for analysis and prognosis of disease states. None of the available documents, either alone or in combination, discloses such an introduction of an image mining technique to proteome analysis, which appears non-obvious to a person skilled in the art.

Claims 2-11 and claims 13-20 are dependent on claim 1 and claim 12, respectively. Therefore, the system to which claims 1-11 relate and the method to which claims 12-20 do are believed to be novel and to involve an inventive step as compared with prior arts fulfilling the requirements set forth in Article 33(2)&(3) PCT.

The subject matter of claim 21 is biomarkers comprising a novel proteome pattern specific to diagnosis of breast cancer, which has been generated by the method of the present invention. Claim 21 thus complies with the requirements set forth in Article 33(2)&(3) PCT.

#### 2. Industrial applicability

Present invention relates to a computer-based system, a method and biomarkers for detection of cancer. There is no reason to negate the industrial applicability of this invention. Consequently, claims 1-21 appear to meet the requirements of Article 33(4) PCT.